The Jackson Laboratory
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
9
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Functional Oligodendrocytes Derived from Pluripotent Stem Cells and Methods of Making and Using the Same (US 10,301,592) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 13, 2026The maintenance fee for Breast Cancer Splice Variants (US 11,674,187) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 5 fees due Feb 1 to 22, 2027 · next Feb 1
- 1 fee due Mar 8, 2027The maintenance fee for Mouse Having Human Leukemic Stem Cell and Leukemic Non-Stem Cell Amplified Therein, and Method for Production Thereof (US 9,125,384) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 6 fees due Apr 1 to 29, 2027 · next Apr 1
- 1 fee due May 14, 2027The maintenance fee for Functional Oligodendrocytes Derived from Pluripotent Stem Cells and Methods of Making and Using the Same (US 11,814,648) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Optical Pressure Treatment through Electrical Stimulation (US 10,493,274) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Jul 19, 2027The maintenance fee for Compositions and methods relating to non-human animals modified to promote production of selected gametes (US 9,237,740) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Methods for promoting wound healing and hair growth comprising GDNF administration (US 11,890,322) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 3 fees due Oct 16, 2027
- 1 fee due Nov 7, 2027The maintenance fee for Gene mutations associated with tandem duplicator phenotype (US 11,978,556) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,420,307 | Sperm cryoprotective media In force · From the USPTO record | In force | From the USPTO record | |
| US 8,685,637 | Kit for sperm cryoprotection In force · From the USPTO record | In force | From the USPTO record | |
| US 7,881,873 | Systems and methods for statistical genomic DNA based analysis and evaluation In force · From the USPTO record | In force | From the USPTO record | |
| US 8,318,670 | Antigens Targeted by Pathogenic AL4 T Cells in Type 1 Diabetes and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,136,377 | Antibodies and Fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,435,729 | Sperm cryoprotective media In force · From the USPTO record | In force | From the USPTO record | |
| US 9,789,336 | Methods for protecting eyes against neurodegeneration caused by glaucoma in age-related hereditary glaucoma using radiation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,457,719 | Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,669,289 | Methods and compositions relating to hematologic malignancies In force · From the USPTO record | In force | From the USPTO record | |
| US 9,125,384 | Mouse Having Human Leukemic Stem Cell and Leukemic Non-Stem Cell Amplified Therein, and Method for Production Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 82: 8 patents in force now held by others · 9 lapsed for an unpaid fee · 27 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
43 pending · 18 abandoned · 57 no status recorded